Adults 65 and older should preferentially receive one of three influenza vaccines — high-dose inactivated, recombinant, or adjuvanted — rather than a standard-dose product, and should not delay vaccination if only a standard product is available, according to guidance reporting for the 2026–27 season.
The preference exists because the risk is concentrated. Older adults account for an estimated 70 to 85 percent of seasonal influenza deaths and 50 to 70 percent of hospitalisations in the figures cited in clinical coverage — the statistical reason influenza policy, across every wealthy country’s programme, is substantially a policy about this age group. Immune response declines with age; the three preferred products answer that decline differently. High-dose vaccine quadruples the antigen. The recombinant product delivers a larger, precisely manufactured dose without egg-based production. The adjuvanted vaccine adds an ingredient whose entire job is to provoke a stronger response from an ageing immune system. All three have shown better protection than standard-dose in this age group in the evidence the guidance rests on; none is ranked so far above the others that waiting for a specific brand is wise.
Hence the second clause, which clinicians repeat because patients keep violating it: do not delay. A standard-dose vaccine received in October protects better than a preferred product received after exposure in December. Supply varies by pharmacy and week; the guidance’s instruction is to take the age-appropriate vaccine that is in the refrigerator in front of you if the preferred three are not, and to record which product was given rather than re-vaccinate within the season.
Timing has an older-adult nuance. Because protection wanes measurably over a season, vaccinating in July or August — when eager pharmacies open their lists — risks arriving at the February peak with the weakest coverage; the guidance steers this group toward September and October and completion by the end of October where possible. Healthcare personnel and long-term-care staff sit inside the same recommendation from the other direction: their vaccination is part of their residents’ protection, which is why facilities track it as a safety metric rather than a personal choice statistic.
Influenza will find older lungs this winter, as it does every winter; the only variable the system controls is how many of those encounters were rehearsed by a vaccine first. Three products are preferred, one rule governs — vaccinated on time beats perfectly vaccinated late. This is general information only; individual decisions belong with your clinician.
Related reading:
